• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit.

作者信息

Hermon Michael M, Golej Johann, Burda Gudrun, Boigner Harald, Stoll Elisabeth, Vergesslich Klara, Strohmaier Wolfgang, Pollak Arnold, Trittenwein Gerhard

机构信息

Department of Neonatology and Paediatric Intensive Care, University Children's Hospital, University of Vienna, Austria.

出版信息

Shock. 2002 Apr;17(4):247-51. doi: 10.1097/00024382-200204000-00001.

DOI:10.1097/00024382-200204000-00001
PMID:11954821
Abstract

Despite the established success of surfactant application in neonates, the use of surfactant in older children is still a matter of discussion. We hypothesized that surfactant application in children with acute respiratory distress syndrome (ARDS) secondary to a pulmonary or systemic disease or after cardiac surgery improves pulmonary function. We also asked whether repeated treatment could further improve pulmonary function. To answer these questions, we measured oxygenation index (OI) and hypoxemia score after the first and after a second application of surfactant (50-100 mg/kg body wt) at least 24 h later. We enrolled 19 children (older than 4 weeks) for a retrospective chart review study, and six of them underwent cardiac surgery. Demographic data were extracted. OI and hypoxemia score were estimated before and 2 and 24 h after surfactant application. Lung injury score was calculated before and 24 h after surfactant application. Outcome measures included survival, duration of mechanical ventilation, and pediatric ICU and hospital stay. The median patient age was 9.0 (quarter percentile 3.7/25) months. The median weight was 8.4 (4.1/11.5) kg. The median lung injury score before the first surfactant application was 2.3 (2.3/2.6). Hospital duration and pediatric ICU stay for all patients was 31.0 (20.0/49.5) days and 27.0 (15.5/32.5) days, respectively. The duration of mechanical ventilation was 24.0 (18.5/31.0) days. The overall mortality was 53%. Twenty-four hours after the first surfactant application, pulmonary function significantly improved. The median OI was 14 (5.5/26) before and 7 (4.5/14.5) 24 h after surfactant application (P= 0.027). The hypoxemia score was 91.7 (69.9/154.2) before and 148.4 (99.2/167.6) 24 h after surfactant application (P = 0.0026). Seven children received a second application, which did not further improve pulmonary function. The lung injury score was not influenced by either surfactant application. We conclude that a single surfactant application improves pulmonary function in children with ARDS. A second application of surfactant showed no further benefit. Outcome was not affected in our study population.

摘要

相似文献

1
Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit.
Shock. 2002 Apr;17(4):247-51. doi: 10.1097/00024382-200204000-00001.
2
Beneficial effect of exogenous surfactant in infants suffering acute respiratory distress syndrome after cardiac surgery.外源性表面活性剂对心脏手术后急性呼吸窘迫综合征婴儿的有益作用。
Eur J Cardiothorac Surg. 2011 Sep;40(3):557-62. doi: 10.1016/j.ejcts.2011.01.008. Epub 2011 Mar 2.
3
Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.外源性表面活性剂(卡肺表面活性素)对小儿急性肺损伤的影响:一项随机对照试验。
JAMA. 2005 Jan 26;293(4):470-6. doi: 10.1001/jama.293.4.470.
4
Effect of low-dose exogenous surfactant on infants with acute respiratory distress syndrome after cardiac surgery: a retrospective analysis.心脏手术后急性呼吸窘迫综合征婴儿应用小剂量外源性表面活性剂的效果:回顾性分析。
BMC Pulm Med. 2020 Aug 6;20(1):210. doi: 10.1186/s12890-020-01251-2.
5
A shared protocol for porcine surfactant use in pediatric acute respiratory distress syndrome: a feasibility study.儿科急性呼吸窘迫综合征中猪肺表面活性剂使用的共享方案:一项可行性研究。
BMC Pediatr. 2019 Jun 18;19(1):203. doi: 10.1186/s12887-019-1579-3.
6
Surfactant treatment for congenital heart disease patients with acute respiratory distress syndrome.
Congenit Heart Dis. 2010 Nov-Dec;5(6):624-8. doi: 10.1111/j.1747-0803.2010.00412.x.
7
Surfactant application during extracorporeal membrane oxygenation improves lung volume and pulmonary mechanics in children with respiratory failure.体外膜肺氧合期间应用表面活性剂可改善呼吸衰竭患儿的肺容积和肺力学。
Crit Care. 2005;9(6):R718-24. doi: 10.1186/cc3880. Epub 2005 Oct 25.
8
Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome.表面活性剂可改善患有肺炎和急性呼吸窘迫综合征的婴幼儿的氧合作用。
Acta Paediatr. 2002;91(11):1174-8. doi: 10.1080/080352502320777397.
9
Surfactant therapy for acute respiratory distress in severe pediatric burn injury: a case series.表面活性剂治疗小儿严重烧伤后急性呼吸窘迫:病例系列
J Burn Care Res. 2012 Mar-Apr;33(2):e88-91. doi: 10.1097/BCR.0b013e31823356fc.
10
[Surfactant-BL and inhaled nitric oxide in acute respiratory distress syndrome in cardiac surgical patients].[表面活性物质BL与吸入一氧化氮用于心脏手术患者急性呼吸窘迫综合征的治疗]
Anesteziol Reanimatol. 2005 Nov-Dec(6):38-41.

引用本文的文献

1
40 years neonatology : An academic life.40年新生儿学:学术生涯。
Wien Klin Wochenschr. 2025 Feb;137(3-4):69-78. doi: 10.1007/s00508-024-02360-2. Epub 2024 Apr 18.
2
A shared protocol for porcine surfactant use in pediatric acute respiratory distress syndrome: a feasibility study.儿科急性呼吸窘迫综合征中猪肺表面活性剂使用的共享方案:一项可行性研究。
BMC Pediatr. 2019 Jun 18;19(1):203. doi: 10.1186/s12887-019-1579-3.
3
Monocyte Chemoattractant Protein-1, a Possible Biomarker of Multiorgan Failure and Mortality in Ventilator-Associated Pneumonia.
单核细胞趋化蛋白-1 可能是呼吸机相关性肺炎多器官衰竭和死亡的生物标志物。
Int J Mol Sci. 2019 May 6;20(9):2218. doi: 10.3390/ijms20092218.
4
Pathophysiology and Management of Acute Respiratory Distress Syndrome in Children.儿童急性呼吸窘迫综合征的病理生理学与管理
Pediatr Clin North Am. 2017 Oct;64(5):1017-1037. doi: 10.1016/j.pcl.2017.06.004.
5
Hyperoxia treatment of TREK-1/TREK-2/TRAAK-deficient mice is associated with a reduction in surfactant proteins.对TREK-1/TREK-2/TRAAK基因缺陷小鼠进行高氧治疗会导致表面活性蛋白减少。
Am J Physiol Lung Cell Mol Physiol. 2017 Dec 1;313(6):L1030-L1046. doi: 10.1152/ajplung.00121.2017. Epub 2017 Aug 24.
6
Surfactants in Acute Respiratory Distress Syndrome in Infants and Children: Past, Present and Future.婴幼儿及儿童急性呼吸窘迫综合征中的表面活性剂:过去、现在与未来
Clin Drug Investig. 2017 Aug;37(8):729-736. doi: 10.1007/s40261-017-0532-1.
7
Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.儿童急性呼吸窘迫综合征:纤维化与修复。
Front Pediatr. 2016 Mar 30;4:28. doi: 10.3389/fped.2016.00028. eCollection 2016.
8
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.表面活性物质治疗急性肺损伤和急性呼吸窘迫综合征。
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
9
Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.急性肺损伤和急性呼吸窘迫综合征的药物治疗
Curr Med Chem. 2008;15(19):1911-24. doi: 10.2174/092986708785132942.
10
Surfactant for pediatric acute lung injury.用于小儿急性肺损伤的表面活性剂
Pediatr Clin North Am. 2008 Jun;55(3):545-75, ix. doi: 10.1016/j.pcl.2008.02.016.